Solventum
Global healthcare company: wound care, dental
Autonomous Coding Integration Specialist
+ Variable incentive pay
Remote role with up to 20% domestic/international travel. Initial on-site onboarding is required.
About the job
- An associate degree or higher, or seven years of computer or data integration experience; alternatively, a high school diploma or GED and eleven years of computer or data integration experience.
- At least three years of experience working with Health Level Seven (HL7) and/or Fast Healthcare Interoperability Resources (FHIR) healthcare integration.
- At least three years of experience supporting Hospital Billing and/or Professional Billing workflows.
- At least three years of experience with HL7 messaging standards including ADT, ORM, ORU, MDM, and DFT; Epic integration architecture; Charge Router concepts and billing integrations; and interface testing and troubleshooting.
- Ability to manage multiple projects and priorities simultaneously.
- Customer-focused mindset with demonstrated consultative skills.
- Design, configure, validate, and troubleshoot HL7 and FHIR interfaces, including ADT, ORM, ORU, MDM, and financial interfaces.
- Collaborate with client integration teams, Epic analysts, and implementation consultants to ensure successful deployment of autonomous solutions.
- Support interface testing, workflow validation, and go-live readiness activities.
- Ensure inbound and outbound data flows meet business and technical requirements.
- Support charge capture, charge routing, coding, and billing processes within Epic environments.
- Assist in validating autonomous coding outputs and downstream billing outcomes.
- Serve as a key liaison among Product Management, Engineering, Implementation Services, Customer Success, and Support teams.
- Assist implementation teams with complex production issues and root-cause analysis.
- Develop innovative approaches to integration challenges and operational workflows.
- Contribute to best practices, implementation playbooks, and technical documentation.
- Transform emerging ideas into scalable solutions that improve customer outcomes and accelerate adoption of autonomous technologies.
- Comply with corporate policies, procedures, and security standards while performing assigned duties.
- Epic certification or accreditation.
- Strong analytical and problem-solving abilities.
- Ability to build strong partnerships across product, implementation, and customer-facing organizations.
- Ability to drive rapid deployment and adoption of autonomous healthcare solutions.
- Experience with autonomous coding, computer-assisted coding, clinical documentation improvement, or healthcare artificial intelligence solutions.
- Post-secondary education in Computer Science or Healthcare Information Technology.
- Ability to bring creative ideas forward and successfully execute them.
About the company
Solventum provides a wide range of healthcare products across four main areas: wound care and surgical supplies, dental and orthodontic tools, health information software, and purification filters for biopharmaceuticals. These products work by combining material science and data science to help hospitals manage patient records, prevent infections during surgery, and filter fluids for medical treatments like dialysis. Unlike many competitors, the company holds a massive portfolio of over 7,300 patents inherited from its history as a 3M division, allowing it to serve over 75% of U.S. hospitals. Its goal is to use this intellectual property and a disciplined business model to find new solutions for healthcare providers and grow within the global medical technology market.
Company Size
10,001+
Company Stage
IPO
Headquarters
Maplewood, Minnesota
Founded
2023
Get referred to Solventum
See people who can refer or advise you
Simplify's Take
What believers are saying
- Q2 2026 organic sales rose 9.5%, and management lifted EPS guidance to $7.10-$7.20.
- Dental grew 15.2% organically in Q2 2026, showing pricing and product momentum.
- Solventum exited nearly 70% of TSAs and targets 90% by end-2026.
What critics are saying
- ERP advance orders inflated Q2 by about $125 million, and Q3 reverses.
- HIS now faces separation, and AI-native competitors threaten revenue-cycle workflows by 2027.
- Thermo Fisher's $4.1 billion filtration acquisition removes Solventum's fastest-growing cash engine.
What makes Solventum unique
- Solventum controls 3M-origin IP, with 7,300 patents across MedSurg, dental, and filtration.
- Its $200 million Eagan Innovation Hub centralizes wound care, sterilization, and digital health R&D.
- Management expects nearly 20 launches through Q1 2028, anchoring category depth.
Help us improve and share your feedback! Did you find this helpful?
Benefits
Health Insurance
Dental Insurance
Vision Insurance
Life Insurance
Disability Insurance
Health Savings Account/Flexible Spending Account
Remote Work Options
Paid Vacation
Paid Sick Leave
Paid Holidays
Hybrid Work Options
Relocation Assistance
Growth & Insights and Company News
6 month growth
↑ 5%1 year growth
↑ 5%2 year growth
↑ 8%BrightSpring Health Services stands out as a strong long-term healthcare investment, whilst Solventum and Inspire Medical Systems face headwinds, according to recent analysis. Healthcare stocks have surged 27.5% over the past six months, outperforming the S&P 500 by 16.2 percentage points. However, increased venture capital has intensified competition across the sector. BrightSpring, which provides home health care, hospice, and pharmacy services, has achieved 23.9% annual revenue growth over the past two years. Analysts forecast 14.1% revenue growth for the next 12 months. Conversely, Solventum faces weak demand with flat revenue expected, whilst its free cash flow margin has declined 18.2 percentage points over five years. Inspire Medical Systems confronts a forecasted revenue decline of 3.5% for the upcoming year.
Healthcare solutions provider Solventum reported second quarter revenue of $2.21 billion, up 2.2% year on year and ahead of analyst estimates of $2.15 billion. Non-GAAP profit of $2.55 per share beat consensus estimates by 33.8%. The company announced plans to separate its Health Information Systems business to focus on its MedSurg and Dental segments. Management said the move would allow the HIS unit to pursue AI-driven innovation whilst sharpening Solventum's focus as a pure-play MedTech company. Second quarter results were temporarily boosted by approximately $125 million in advanced orders placed ahead of a major ERP system transition, which management expects to reverse next quarter. The company raised its full-year adjusted EPS guidance to $7.15 at the midpoint, a 10% increase. Solventum is nearing completion of its separation from 3M.
Solventum exceeded expectations in Q2, posting $2.2 billion in sales with 9.5% organic growth. However, this included roughly $125 million in advanced ERP-related orders and a $100 million tariff refund. Excluding these benefits, organic growth was approximately 4% and adjusted EPS was estimated at $1.73. The company raised its 2026 outlook, now expecting 2.5%–3% organic sales growth, a 22.2%–22.7% operating margin, adjusted EPS of $7.10–$7.20, and free cash flow of $200 million–$300 million. Third-quarter growth is expected to decline temporarily as the advanced orders reverse. Solventum also announced plans to separate its Health Information Systems business through a potential spin-off or sale, aiming to focus on its MedSurg and Dental segments.
Solventum reported second quarter 2026 sales of $2.2 billion, up 2.2% on a reported basis and 9.5% organically. The MedTech company posted GAAP diluted earnings per share of $0.53 and adjusted diluted EPS of $2.55, marking a 50.9% increase. Operating cash flow reached $227 million, whilst free cash flow totalled $144 million. The strong performance was driven by volume and product mix across all segments, including advance orders ahead of ERP cutovers. Solventum announced plans to separate its Health Information Systems business segment as part of its transformation strategy. The company raised its full-year 2026 guidance, increasing organic sales growth to 2.5% to 3.0%, adjusted EPS to $7.10 to $7.20, and free cash flow to $200 million to $300 million.
Solventum has appointed Neil Zieselman as Senior Vice President, Controller, and Chief Accounting Officer. He will succeed Mary Wilcox, who is retiring. Zieselman brings experience from Surgery Partners, Stryker Corporation, Covanta Holding Corporation, Cendant Corporation, and Avaya. He is a licensed CPA. The company's stock trades at $85.44. It has delivered a 9.5% return over the past week and 19.1% over the past year. For investors, Zieselman's background in healthcare and corporate finance may influence Solventum's financial controls, reporting quality, and regulatory engagement. His approach could shape disclosure practices and capital allocation commentary in future earnings calls. Interest payments are not well covered by earnings, making any changes under the new Chief Accounting Officer particularly important for risk assessment.